Eckert & Ziegler: One-Off Effects and Robust Operating Business Push Nine-Month Result to Record Level

DGAP-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): 9 Month figures
09.11.2021 / 07:45
The issuer is solely responsible for the content of this announcement.

Berlin, 9 November 2021. Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, TecDAX), achieved a record result in the first nine months of 2021 with a net profit of € 29.2 million or € 1.41 per share. By the end of September, earnings had thus already exceeded those of the entire previous year by € 11.6 million or 65%. Adjusted for the tumor irradiation business, which has been sold in the meantime, Group sales totaled € 126 million, up € 9 million or 8% on the previous year's level.

Although a large part of the 2021 earnings growth resulted from the sale of the tumor device business, the development of the operating business in both segments was also extremely encouraging. Adjusted for one-off effects of € 9.1 million, earnings before interest and taxes (EBIT) in the Medical segment rose by 28% from € 15.6 million to € 19.9 million. In the Isotope Products segment, EBIT increased even more by 44% from € 7.7 million to € 11.1 million. In this segment, the return to the pre-Corona earnings level has stabilized. The holding company closed the nine-month period with EBIT of € 0.3 million. In total, the segment earnings added up to a Group EBIT of more than € 40 million.

The Medical segment was able to increase its sales revenues by € 6.7 million or 14%, adjusted for the revenues from the tumor irradiation business, which was still included in the previous year and has since been sold. Sales to pharmaceutical companies developed dynamically, with orders for services and products relating to radiopharmaceuticals and pharmaceutical radioisotopes up by around 16%. Sales of laboratory equipment, brachytherapy and other products and services increased by 9%.

The Isotope Products segment generated sales of € 73.1 million, around 5% higher than in the first nine months of 2020. Net profit rose by almost 55%. Following the slumps in connection with the COVID pandemic last year, the segment was thus able to return to the growth path as expected.

Based on the nine-month figures, the Executive Board continues to confirm the previously issued sales and earnings guidance of approximately € 180 million, or around € 1.70 per share.

The complete quarterly report can be viewed here:
https://www.ezag.com/fileadmin/user_upload/ezag/investors-financial-reports/englisch/euz321e.pdf

About Eckert & Ziegler.
Eckert & Ziegler Strahlen- und Medizintechnik AG with more than 800 employees is a leading specialist for isotope-related components in nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.
Contributing to saving lives.

Your contact:
Eckert & Ziegler AG, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@ezag.de, www.ezag.com

09.11.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de